Top Stock #1:
Quest Diagnostics (DGX)
I predicted that Quest Diagnostics (DGX) was poised for another round of great earnings, and I was
right. In the second quarter, DGX reported a 17% profit increase thanks to a jump in clinical testing revenue. As a result, this stock posted a decent
The laboratory operator earned $188.2 million or $1 per share, compared with $161.3 million or 82 cents per share last year. Revenue increased 3%
to $1.9 billion. Analysts were expecting earnings of 95 cents per share on total sales of $1.89 billion, so Quest easily beat the Street.
Thanks to the company’s better-than-expected results, DGX raised its full-year profit outlook for the second time this year, which is great news
for investors. Demand for Quest’s clinical testing services is going strong, so make sure you’re well-positioned in this stock now so you can ride
its upward momentum all the way to top.
This company is the leading provider of independent diagnostic testing in the U.S., and has seen very strong sales even amid weak consumer spending.
We have already seen a nearly double-digit return in Quest since our purchase in the June issue of Blue Chip Growth,
and I expect further success for us.